Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Weighted Average) (2016 - 2025)

Seres Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $8.7 million for Q1 2025.

  • For Q1 2025, Shares Outstanding (Weighted Average) rose 19.14% year-over-year to $8.7 million; the TTM value through Mar 2025 reached $8.7 million, up 19.14%, while the annual FY2024 figure was $155.4 million, 21.4% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2025 was $8.7 million at Seres Therapeutics, down from $155.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $155.4 million in Q4 2024 and bottomed at $7.3 million in Q1 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $100.2 million (2022), against an average of $101.0 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 38.43% in 2023 before it plummeted 94.2% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $91.7 million in 2021, then rose by 17.86% to $108.1 million in 2022, then grew by 18.44% to $128.0 million in 2023, then increased by 21.4% to $155.4 million in 2024, then crashed by 94.4% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Shares Outstanding (Weighted Average) are $8.7 million (Q1 2025), $155.4 million (Q4 2024), and $152.6 million (Q3 2024).